Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
तुलना करने के लिए मीट्रिक्स | ELOX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधELOXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.5x | −0.6x | |
PEG अनुपात | 0.00 | −0.03 | 0.00 | |
क़ीमत/बुक | 0.0x | −0.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 5.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 2,999,900.0% | 160.4% | 44.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.8% | 6.2% | अनलॉक करें |